Walleye Capital’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Walleye Capital’s Portfolio SPPI Stock Details SPPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-230,839	Closed	-$537K	–	1064
2020 Q1	$537K	Buy	+230,839	New	+$632K	0.12%	215
2019 Q4	–	Sell	-26,372	Closed	-$213K	–	2377
2019 Q3	$219K	Buy	+26,372	New	+$213K	0.01%	1163
2018 Q3	$98K	Buy	+5,828	New	+$126K	0.05%	258

Other funds holding SPPI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Walleye Capital's SPPI Position: Q2 2020 in Review

Walleye Capital sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q2 2020, closing a stake of 230,839 shares — an estimated $537K sold.

Walleye Capital first reported a position in SPPI in Q3 2018 and held it in 3 quarters. The position peaked at $537K in Q1 2020. 158 funds tracked by Wall St. Rank hold SPPI as of Q2 2020.

Walleye Capital reported no remaining Spectrum Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Walleye Capital sold 230,839 Spectrum Pharmaceuticals Inc shares in Q2 2020, an estimated $537K.
Walleye Capital first reported a position in Spectrum Pharmaceuticals Inc in Q3 2018 and held it in 3 quarters.
Walleye Capital's Spectrum Pharmaceuticals Inc position peaked at $537K in Q1 2020.
158 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q2 2020.

Based on Walleye Capital's 13F filing for Q2 2020, filed 14 Aug 2020.